References:
1. Hunger SP, Lu, X., Devidas, M., Camitta, B.M., Gaynon, P.S., Winick,
N.J.,, Reaman GH, Carroll, W.L. . Improved Survival for Children and
Adolescents With Acute Lymphoblastic Leukemia Between 1990 and 2005: A
Report From the Children’s Oncology Group. Journal of Clinical
Oncology. 2012;30(14):1663 - 1669.
2. Pui CH, Mullighan, C.G., Evans, W.E., Relling, M.V. Pediatric acute
lymphoblastic leukemia: where are we going and how do we get there?Blood. 2012;120(6):1165-1174.
3. Gorman MF, Ji, L., Ko, R.H., Barnette, P., Bostrom, B., Hutchinson,
R., Raetz, E., Seibel, N.L., Loh, M.L., et al. . Outcome for Children
Treated for Relapsed or Refractory Acute Myelogenous Leukemia (rAML): A
Therapeutic Advances in Childhood Leukemia (TACL) Consortium Study.Pediatric Blood Cancer. 2010;55:421-429.
4. ALL- REZ BFM vS, A. (direcor of studies), Kretschmann, A.
(Documentary). ALL-REZ BFM Beobachtungsstudie und Biobank für Rezidive
einer akuten lymphoblastischen Leukämie im Kindes - und Jugendalter.
version 20.09.2012.
5. Tallen G, Ratei, R., Mann, G., Kaspers, G., Niggli, F., Karachunsky,
A., Ebell, W., Escherich, G., Schrappe, M., Klingebiel, T., Fengler, R.,
Henze, G. Long-Term Outcome in Children With Relapsed Acute
Lymphoblastic Leukemia After Time-Point and Site-of-Relapse
Stratification and Intensified Short-Course Multidrug Chemotherapy:
Results of Trial ALL-REZ BFM 90. Journal of clinical oncology.2010;28 (14 ):2339 - 2347.
6. Bayraktar UD, Bashir, Q., Qazilbash, M., Champlin, R.E., Ciurea, S.O
Fifty Years of Melphalan Use in Hematopoietic Stem Cell Transplantation.Biology of Blood and Marrow Transplantation. 2013;19:344e356.
7. Kato K, Yoshida, N., Matsumoto, K., Matsuyama, T. Fludarabine,
Cytarabine, Granulocyte Colony-Stimulating Factor and Melphalan (FALG
with L-PAM) as a Reduced Toxicity Conditioning Regimen in Children with
Acute Leukemia. Pediatric Blood Cancer. 2014;61:712-716.
8. Oshrine B, Adams, L., Nguyen, A.T.H., Amankwah, E., Shyr, D., Hale,
G., Petrovic, A. Comparison of melphalan- And busulfan-based
myeloablative conditioning in children undergoing allogeneic
transplantation for acute myeloid leukemia or myelodysplasia.Pediatric Transplantation. 2020:1 - 8.
9. Stentofi J. The Toxicity of Cytarabine. Drug Safety.1990;5:7-27.
10. AML-BFM-Study Group Coordination: Reinhardt D, Creutzig, U.
International Registry Relapsed AML 2009 Registry of children and
adolescents with relapsed or refractory acute myeloid leukemia (AML).
2009.
11. von Stackelberg A, Locatelli, F, Zugmaier, G., Handgretinger, R.,
Trippett, T.M., Rizzari, C., Bader ,P., O’Brien, M.M., Brethon, B.,
Bhojwani, D., Schlegel, P.G., Borkhardt, A., Rheingold, S.R., Cooper,
T.M., Zwaan, C.M., Barnette, P., Messina, C., Michel, G., DuBois, S.G.,
Hu, K., Zhu, M., Whitlock, J.A., Gore, L. Phase I/Phase II Study of
Blinatumomab in Pediatric Patients With Relapsed/Refractory Acute
Lymphoblastic Leukemia. journal of Clinical Oncology.2016;34(36):4381 - 4389.
12. Gore L, Locatelli, F. Zugmaier, G., Handgretinger, R., O’Brien,
M.M., Bader, P., Bhojwani, D., Schlegel, P.-G., Tuglus, C.A., von
Stackelberg, A. Survival after blinatumomab treatment inpediatric
patients with relapsed/refractoryB-cell precursor acute
lymphoblasticleukemiaLia BloodCancerJournal. 2018;8(9).
13. Maude SL, Laetsch, T.W., Buechner, J., Rives, S., Boyer, M.,
Bittencourt, H., Bader, P., Verneris, M.R., Stefanski, H.E., Myers,
G.D., Qayed, M., De Moerloose, B., Hiramatsu, H., Schlis, K., Davis,
K.L., Martin, P.L., Nemecek, E.R., Yanik, G.A., Peters, C., Baruchel,
A., Boissel, N., Mechinaud, F., Balduzzi, A., Krueger, J., June, C.H.,
Levine, B.L., Wood, P., Taran, T., Leung, M., Mueller, K.T., Zhang, Y.,
Sen, K., Lebwohl, D., Pulsipher, M.A., Grupp, S.A. Tisagenlecleucel in
Children and Young Adults with B-Cell Lymphoblastic Leukemia. New
England Journal of Medicine. 2018;378(5):439 - 448.
14. Abrahamsson J, Clausen, N., Gustafsson, G., Hovi, L., Jonmundsson,
G., Zeller, B., Forestier, E., Heldrup, J., Hasle, H. . Improved outcome
after relapse in children with acute myeloid Leukaemia. British
journal of haematology. 2007;136:229-236.
15. Creutzig U. S, J., Kaspers, G.L., Reinhardt, D., Zimmermann, M.
Re-induction with L-DNR/FLAG Improves Response after AML Relapse, but
not Long-term Survival. Klinische Pädiatrie. 2014;226:323 - 331.
16. AIEOP-BFM study group. Coordinating principal investigator: Schrappe
M. AIEOP-BFM ALL 2017: International collaborative treatment protocol
for children and adolescents with acute lymphoblastic leukemia: A
randomized phase III study conducted by the AIEOP-BFM study group.
Protocol version 1.5. EudraCT Number AIEOP-BFM ALL 2017: 2016-001935-12
2018.
17. Mustafa O, Abdalla, K., AlAzmi, A.A., Elimam, N., Abrar, M.B.,
Jastaniah, W. FLAG/FLAG-IDA regimen for children with
relapsed/refractory acute leukemia in the era of targeted novel
therapies Journal of Oncology Pharmacy Practice. 2019;25(8):1831
- 1838.
18. Keshu Zhou YS, Yanli Zhang, Xudong Wei, Yuewen Fu, Fengkuan Yu, Hu
Zhou, Xinjian Liu, Jian Zhou, Baijun Fang. Efficacy and safety of G-CSF,
low-dose cytarabine and aclarubicin in combination with L-asparaginase,
prednisone in the treatment of refractory or relapsed acute
lymphoblastic leukemia. Leukemia Research. 2017;62 29-33.
19. Steckel NK, Groth C., Mikesch, J.-H., Trenschel, R., Ottinger, H.,
Kordelas, L., Mueller‐Tidow, C., Schliemann, C., Reicherts, C. High‐dose
melphalan‐based sequential conditioning chemotherapy followed by
allogeneic haematopoietic stem cell transplantation in adult patients
with relapsed or refractory acute myeloid leukaemia. British
journal of haematology. 2018;180(6):840 - 853.
20. Spitzer B, Perales, M.-A., Kernan, N.A., Prockop, S.E., Zabor, E.C.,
Webb, N., Castro-Malaspina, H., Papadopoulos, E.B., Young, J.W.,
Scaradavou, A., Kobos, R., Giralt, S.A., O’Reilly, R.J., Boulad, F.
Second allogeneic stem cell transplantation for acute leukemia using a
chemotherapy only cytoreduction with clofarabine, melphalan, and
thiotepa. Biology of Blood and Marrow Transplantation.2016;22(8):1449 - 1454.
FIGURE 1: Overall survival rate of the whole cohort (n=8) after a
salvage therapy with melphalan and cytarabine with a one year survival
of 50% (n=4) and a three year survival of 29% (n=2)